RecruitingNot ApplicableNCT05794464

The SAFE Prospective Registry

Secretoneurin as a Biomarker of Atrial Fibrillation rEcurrence After Catheter Ablation/Electrical Cardioversion

Sponsor

University Hospital Ostrava

Enrollment

60 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Atrial Fibrillation, Paroxysmal or Persistent

Summary

Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building a registry (a detailed database) to track patients with atrial fibrillation (AFib — an irregular heartbeat) who are undergoing catheter ablation or electrical cardioversion (procedures used to restore normal heart rhythm). The goal is to understand outcomes and identify useful biological markers. **You may be eligible if...** - You have paroxysmal or persistent atrial fibrillation (AFib that comes and goes, or lasts for weeks/months) - You are scheduled for catheter ablation or electrical cardioversion - You have signed informed consent **You may NOT be eligible if...** - You have long-standing or permanent AFib - You have severe mitral valve leakage, heart failure with permanently reduced pumping, a recent stroke (within 3 months), or severe kidney or liver problems - You have had a recent heart attack Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.